35 results about "Triptans" patented technology

A composition of a triptan and particles of a NSAID. The NSAID particles having an effective average particle size of less than 2000 nm and at least one surface stabilizer adsorbed on the surface thereof. The NSAID component of the composition, in a comparative pharmacokinetic testing with a non-particulate NSAID in the same dosage strength and form, exhibits a shorter time to Tmax when compared to the time to Tmax of the non-nanoparticulate NSAID.

The present invention is directed to dosage forms that can be used in therapeutic methods involving the oral co-administration of a combination of at least two drugs, one of which impairs gastrointestinal absorption and one of which does not. The dosage forms are designed so that the drug impairing absorption is not released into the gastrointestinal tract of a patient until after the drugs that do not impair absorption have been released and substantially absorbed. The invention may be used in treatment of migraine using a combination of triptans and NSAIDs or in the treatment of pain using a combination of NSAIDs and opioid analgesics.

Formulations for and methods of treatment of Dravet syndrome that avoid side effects are disclosed. The formulations comprise a 5-HT receptor agonists which does not agonize selected 5-HT receptor subtypes, and in particular does not agonize the receptor subtype 5-HT2B. Also disclosed are combinations of such 5-HT receptor agonists. Also disclosed are combinations of such 5-HT receptor agonists and SSRIs, SNRIs, and triptans for treating co-morbidities associated with Dravet syndrome.

Rapidly disintegrating oral triptan formulations having superior palatability and methods of making such are provided herein. A rapidly disintegrating oral triptan composition can comprise a triptan compound, a resin, a lubricant, a disintegrant, and a compressible material, where the triptan is admixed with the resin forming a taste-masked triptan composition, which is further admixed with the lubricant, the disintegrant, and the compressible material to form the rapidly disintegrating oral triptan composition.

The present invention relates to, among other things, methods for treating trigeminal cephalgias such as migraine and migraine like headaches and other cerbrovascular conditions associated with pain and or inflammation. When non-steroidal anti inflammatory drugs (NSAIDs), such as ketoprofen, are applied locally using specific topical formulations immediate relief of pain is obtained. Intense pain is typically reduced to mild pain or no pain within 30 minutes of application of the topical formulation. The NSAID may be given in combination with other pharmacological agents, such as vasoconstrictors, opioids, decongestants and / or non-opioid migraine drugs, such as triptans and ergots an agents than affect serotonin receptors as agonists, antagonists or partial agonists. Drugs are delivered locally, targeting the nerve endings of the trigeminal nerve, as well as the occipital nerve and the intranasal terminals of the parasympathetic fibers originating in the Sphenopalatine ganglion. The administration preferably targets the extra cranial nerve endings of the trigeminal nerve in the temporal area, the extracranial occipital nerve endings in the occipital area, and the intranasal terminals of the trigeminal nerve and parasympathetic fibers originating in the Sphenopalatine ganglion. The delivery is carried out topically by way of injection or by transdermal application.

A patch and compositions for iontophoresis of triptan compounds are described.

The present invention provides for a composition comprising a tryptamine based drug that acts as a 5-hydroxytryptamine-1 inhibitor in an amount sufficient to reduce the effects of psoriasis and wherein the composition is formulated for topical or oral administration.